{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:28:51Z","timestamp":1789025331155,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T00:00:00Z","timestamp":1527206400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s11886-018-0997-4","type":"journal-article","created":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T08:06:51Z","timestamp":1527235611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events"],"prefix":"10.1007","volume":"20","author":[{"given":"Sara","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,25]]},"reference":[{"issue":"5","key":"997_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2165\/00003088-199732050-00005","volume":"32","author":"H Lennern\u00e4s","year":"1997","unstructured":"Lennern\u00e4s H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Clin-Pharmacokinet. 1997;32(5):403\u201325. \n                      https:\/\/doi.org\/10.2165\/00003088-199732050-00005\n                      \n                    .","journal-title":"Clin-Pharmacokinet"},{"key":"997_CR2","doi-asserted-by":"publisher","unstructured":"Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, et al. Very low levels of atherogenic lipoproteins and risk of cardiovascular events; a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64(5):485\u201394. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2014.02.615\n                      \n                    .","DOI":"10.1016\/j.jacc.2014.02.615"},{"issue":"10","key":"997_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11883-016-0611-4","volume":"18","author":"O Bilen","year":"2016","unstructured":"Bilen O, Ballantyne CM. Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate Lyase. Curr Atheroscler Rep. 2016;18(10):61. \n                      https:\/\/doi.org\/10.1007\/s11883-016-0611-4\n                      \n                    .","journal-title":"Curr Atheroscler Rep"},{"issue":"14","key":"997_CR4","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"DM Lloyd-Jones","year":"2017","unstructured":"\u2022\u2022 Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. Focused update of the 2016 ACC Expert Consensus Decision Pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(14):1785\u2013822. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2017.07.745\n                      \n                    . This is the current treatment pathway from the American College of Cardiology.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"997_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jjcc.2008.05.001","volume":"52","author":"S Miura","year":"2008","unstructured":"Miura S, Saku K. Beneficial effects of ezetimibe-based therapy in patients with dyslipidemia. J Cardiol. 2008;52(1):1\u20136. \n                      https:\/\/doi.org\/10.1016\/j.jjcc.2008.05.001\n                      \n                    .","journal-title":"J Cardiol"},{"key":"997_CR6","doi-asserted-by":"publisher","unstructured":"Gagn\u00e9 C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90(10):1084\u201391. \n                      https:\/\/doi.org\/10.1016\/S0002-9149(02)02774-1\n                      \n                    .","DOI":"10.1016\/S0002-9149(02)02774-1"},{"key":"997_CR7","doi-asserted-by":"publisher","unstructured":"\u2022 Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1410489\n                      \n                    . This trial provides evidence that LDL lowering with ezetimibe reduces CV events.","DOI":"10.1056\/NEJMoa1410489"},{"issue":"5","key":"997_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.18773\/austprescr.2016.060","volume":"39","author":"MM Page","year":"2016","unstructured":"Page MM, Watts GF. PCSK9 inhibitors\u2014mechanisms of action. Aust Prescr. 2016;39(5):164\u20137. \n                      https:\/\/doi.org\/10.18773\/austprescr.2016.060\n                      \n                    .","journal-title":"Aust Prescr"},{"issue":"12","key":"997_CR9","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley THJ, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264\u201372. \n                      https:\/\/doi.org\/10.1056\/NEJMoa054013\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"997_CR10","doi-asserted-by":"publisher","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1501031\n                      \n                    .","DOI":"10.1056\/NEJMoa1501031"},{"key":"997_CR11","unstructured":"PRALUENT\u00ae (alirocumab) [package insert]. Sanofi-Aventis U.S. LLC., Bridgewater, NJ. 2015."},{"key":"997_CR12","unstructured":"\u2022 Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab. American College of Cardiology. \n                      http:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2018\/03\/09\/08\/02\/odyssey-outcomes\n                      \n                    . Accessed April 13, 2018. This trial provides evidence that LDL lowering with a PCSK9 inhibitor reduces CV events."},{"key":"997_CR13","unstructured":"Dosing information | Repatha\u00ae (evolocumab). Amgen. \n                      https:\/\/www.repathahcp.com\/dosing\/\n                      \n                    . Published 2017. Accessed February 28, 2018."},{"key":"997_CR14","doi-asserted-by":"publisher","unstructured":"\u2022 Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1615664\n                      \n                    . This trial provides evidence that LDL lowering with a PCSK9 inhibitor reduces CV events.","DOI":"10.1056\/NEJMoa1615664"},{"key":"997_CR15","unstructured":"REPATHA (evolocumab) [package insert]. Amgen Inc., Thousand Oaks, CA. Amgen Inc. 2017 2015."},{"key":"997_CR16","unstructured":"Evolocumab and outcomes in patients with peripheral artery disease. \n                      http:\/\/www.abstractsonline.com\/pp8\/#!\/4412\/presentation\/52463\n                      \n                    . Accessed January 15, 2018."},{"key":"997_CR17","doi-asserted-by":"publisher","unstructured":"Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. November 2017:CIRCULATIONAHA.117.032235. doi:\n                      https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032235","DOI":"10.1161\/CIRCULATIONAHA.117.032235"},{"key":"997_CR18","doi-asserted-by":"publisher","unstructured":"Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: an analysis from FOURIER Circulation. 2018; published April 6, 2018. \n                      https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034309","DOI":"10.1161\/CIRCULATIONAHA.118.034309"},{"key":"997_CR19","unstructured":"Murphy SA, Pedersen TR, Gaciong ZA, et al. Abstract 15100: reduction in total cardiovascular events with the PCSK9 inhibitor evolocumab in patients with cardiovascular disease in the FOURIER Trial. Circulation. 2017;136(Suppl 1):A15100\u20130."},{"issue":"1","key":"997_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/00003495-200767010-00013","volume":"67","author":"GM Keating","year":"2007","unstructured":"Keating GM, Croom KF. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 2007;67(1):121\u201353.","journal-title":"Drugs"},{"issue":"5","key":"997_CR21","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2147\/VHRM.S3390","volume":"4","author":"M Farnier","year":"2008","unstructured":"Farnier M. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vasc Health Risk Manag. 2008;4(5):991\u20131000.","journal-title":"Vasc Health Risk Manag"},{"key":"997_CR22","doi-asserted-by":"publisher","unstructured":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet. 2005;366(9500):1849\u20131861. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(05)67667-2","DOI":"10.1016\/S0140-6736(05)67667-2"},{"issue":"17","key":"997_CR23","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"Group TAS","year":"2010","unstructured":"Group TAS. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563\u201374. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1001282\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"10","key":"997_CR24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/ajhp\/60.10.995","volume":"60","author":"J McKenney","year":"2003","unstructured":"McKenney J. Niacin for dyslipidemia: considerations in product selection. Am J Health Syst Pharm. 2003;60(10):995\u20131005.","journal-title":"Am J Health Syst Pharm"},{"key":"997_CR25","doi-asserted-by":"publisher","unstructured":"Brown BG, Zhao X-Q, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583\u201392. \n                      https:\/\/doi.org\/10.1056\/NEJMoa011090\n                      \n                    .","DOI":"10.1056\/NEJMoa011090"},{"key":"997_CR26","doi-asserted-by":"publisher","unstructured":"Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323(19):1289\u201398. \n                      https:\/\/doi.org\/10.1056\/NEJM199011083231901\n                      \n                    .","DOI":"10.1056\/NEJM199011083231901"},{"issue":"24","key":"997_CR27","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"Investigators TA-H","year":"2011","unstructured":"Investigators TA-H. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255\u201367. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1107579\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"3","key":"997_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"Group TH-TC","year":"2014","unstructured":"Group TH-TC. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203\u201312. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1300955\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"997_CR29","unstructured":"Correction: FDA removes approved indication for coadministration with a statin for niacin and fibrate combination products. American Pharmacists Association. \n                      http:\/\/www.pharmacist.com\/correction-fda-removes-approved-indication-coadministration-statin-niacin-and-fibrate-combination\n                      \n                    . Published April 18, 2016. Accessed February 27, 2018."},{"key":"997_CR30","doi-asserted-by":"publisher","unstructured":"Committee W, Lloyd-Jones DM, Morris PB, et al. 2016 ACC Expert Consensus Decision Pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol 2016;68(1):92\u2013125. doi:\n                      https:\/\/doi.org\/10.1016\/j.jacc.2016.03.519\n                      \n                    , 68.","DOI":"10.1016\/j.jacc.2016.03.519"},{"key":"997_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4137\/CMC.S32667","volume":"10","author":"CE Kosmas","year":"2016","unstructured":"Kosmas CE, DeJesus E, Rosario D, Vittorio TJ. CETP inhibition: past failures and future hopes. Clin Med Insights Cardiol. 2016;10:37\u201342. \n                      https:\/\/doi.org\/10.4137\/CMC.S32667\n                      \n                    .","journal-title":"Clin Med Insights Cardiol"},{"issue":"13","key":"997_CR32","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"Group TH-RC","year":"2017","unstructured":"Group TH-RC. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217\u201327. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1706444\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"997_CR33","unstructured":"Merck announces results of REVEAL outcomes study of anacetrapib, Investigational Medicine for Cardiovascular Disease | Merck Newsroom Home. \n                      http:\/\/www.mrknewsroom.com\/news-release\/research-and-development-news\/merck-announces-results-reveal-outcomes-study-anacetrapib\n                      \n                    . Accessed January 15, 2018."},{"key":"997_CR34","unstructured":"Merck provides update on REVEAL outcomes study of anacetrapib | Merck Newsroom Home. Merck. \n                      http:\/\/www.mrknewsroom.com\/news-release\/research-and-development-news\/merck-provides-update-reveal-outcomes-study-anacetrapib\n                      \n                    . Published June 27, 2017. Accessed June 27, 2017."},{"key":"997_CR35","doi-asserted-by":"publisher","unstructured":"Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41\u201351. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1609243\n                      \n                    .","DOI":"10.1056\/NEJMoa1609243"},{"key":"997_CR36","doi-asserted-by":"publisher","unstructured":"Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430\u201340. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1615758\n                      \n                    .","DOI":"10.1056\/NEJMoa1615758"},{"key":"997_CR37","unstructured":"Trial to evaluate the effect of inclisiran treatment on low density lipoprotein cholesterol (LDL-C) in subjects with heterozygous familial hypercholesterolemia (HeFH) - Full Text View - \n                      ClinicalTrials.gov\n                      \n                    . \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03397121\n                      \n                    . Accessed January 15, 2018."},{"key":"997_CR38","doi-asserted-by":"publisher","unstructured":"Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090\u20138. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(07)60527-3\n                      \n                    .","DOI":"10.1016\/S0140-6736(07)60527-3"},{"key":"997_CR39","doi-asserted-by":"publisher","unstructured":"Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438\u201347. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1400283\n                      \n                    .","DOI":"10.1056\/NEJMoa1400283"},{"issue":"11","key":"997_CR40","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.numecd.2016.07.004","volume":"26","author":"M Bucci","year":"2016","unstructured":"Bucci M, Tana C, Giamberardino MA, Cipollone F. Lp(a) and cardiovascular risk: investigating the hidden side of the moon. Nutr Metab Cardiovasc Dis. 2016;26(11):980\u20136. \n                      https:\/\/doi.org\/10.1016\/j.numecd.2016.07.004\n                      \n                    .","journal-title":"Nutr Metab Cardiovasc Dis"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-018-0997-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-018-0997-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-018-0997-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T23:08:37Z","timestamp":1558739317000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-018-0997-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,25]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["997"],"URL":"https:\/\/doi.org\/10.1007\/s11886-018-0997-4","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,25]]},"assertion":[{"value":"25 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Sara Lee declares that she has no conflict of interest.Christopher P. Cannon reports grants and personal fees from Arisaph, Boehringer Ingelheim, Takeda, Bristol-Myers Squibb, Amgen, and Merck; grants from Janssen and Daichi-Sankyo; and personal fees from GlaxoSmithKline, Lipimedix, Pfizer, Sanofi, Regeneron, Kowa, Alnylam, Amarin, Eisai, and AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"55"}}